Precigen, Inc. (PGEN) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Precigen, Inc. on November 4, 2021. The filing provides preliminary, unaudited financial updates regarding the Company's cash position and operating cash flow for the nine months ended September 30, 2021, in connection with an R&D call. The Company is incorporated in Virginia and trades on the Nasdaq Global Select Market.
Key Financial Metrics
- Cash Position: Cash, cash equivalents, short-term, and long-term investments totaled $181.3 million as of September 30, 2021.
- Operating Cash Flow: Net cash used in operating activities was $41.2 million for the nine months ended September 30, 2021.
- Revenue and Profit: The filing text does not provide a clear value for revenue, net income, or profit margins.
- Debt and Liquidity: Specific debt figures are not disclosed; however, the total liquid assets (cash and investments) are reported at $181.3 million.
Material Changes Versus Prior Period
Net cash used in operating activities decreased significantly compared to the prior year. For the nine months ended September 30, 2021, usage was $41.2 million, compared to $60.6 million for the same period in 2020. This represents a reduction in cash burn of $19.4 million year-over-year.
Guidance, Outlook, and Risks
The Company plans to file its formal quarterly report on Form 10-Q for the period ended September 30, 2021, on or about November 8, 2021. Management explicitly states that the financial information provided in this 8-K is preliminary and unaudited. Actual results have not been finalized by management or reviewed by independent auditors. Investors are cautioned that subsequent information or events may lead to material differences between this preliminary data and the final reported results. The filing also references an attached press release (Exhibit 99.1) containing R&D updates.
Key Facts for Investor Verification
- Verify the final audited cash balance and operating cash flow figures in the upcoming Form 10-Q filing (expected November 8, 2021).
- Confirm the specific drivers behind the $19.4 million reduction in operating cash burn compared to the prior year.
- Review the attached R&D press release (Exhibit 99.1) for updates on clinical progress or pipeline milestones that may impact future capital requirements.
- Monitor for any material changes to the $181.3 million liquidity position between the filing date and the 10-Q release.